No Data
Express News | Aclaris Therapeutics Inc -Files Prospectus for Offer, Resale by Selling Stockholders of up to 35.6 Mln Shares of Common Stock
Jefferies Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7
Aclaris Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Raises Target Price to $5
Stifel Nicolaus Remains a Hold on Aclaris Therapeutics (ACRS)
Sino biopharm (01177.HK) has reached a global cooperation agreement with博奥信 and aclaris therapeutics.
On December 5th, Gelonghui reported that sino biopharm (01177.HK) announced that the group has reached a global cooperation agreement with Aclaris Therapeutics, Inc. concerning their jointly developed TSLP monoclonal antibody "BSI-045B (TQC2731)" with Boaoxin Biotechnology (Nanjing) Co., Ltd. ("Boaoxin").